KEAP1 and non-small cell lung carcinoma: Also, a quantitative high-throughput screening on ∼400 000 small molecules made by Singh and coworkers led to the identification of ML385, a compound with high specificity and selectivity for NSCLC with constitutive NRF2 activation caused by inactivating mutations of KEAP1 (see Table 1).